文献速递免疫规划卫生政策与健康促进

195个国家5岁以下儿童轮状病毒疫苗接种的成本效果:一项Meta回归分析

Cost-effectiveness of rotavirus vaccination in children under five years of age in 195 countries: A meta-regression analysis.
PubMed 文献 · Vaccine · 2022-05-25

该研究基于68篇文章的515个ICER及938项敏感性分析,用五阶段混合效应贝叶斯Meta回归预测195国轮状病毒疫苗接种的ICER,全球中位ICER为2289美元/DALY,疫苗效力、成本、人均GDP和轮状病毒DALY是主要驱动因素。

要点

  • 全球轮状病毒疫苗接种中位ICER为2289美元/DALY(95%UI:147-38993)。
  • Gavi支持国家平均ICER为255美元/DALY(95%UI:39-918)。
  • 疫苗效力、成本、人均GDP和轮状病毒DALY是ICER变异的重要驱动因素。

核心结论

  • 研究结果纳入了疫苗效力因地点而异的最新证据,支持扩大轮状病毒疫苗接种规划,尤其是在有资格获得Gavi支持的国家。

研究设计与样本

  • 基于Tufts大学CEA和全球健康CEA注册库,使用68篇文章的515个ICER,提取938项补充单因素敏感性分析,排除33个ICER后样本为1418个,采用五阶段混合效应贝叶斯Meta回归框架预测ICER,并用逻辑回归模型预测疫苗具有成本节约效应的概率。
  • 协变量包括疫苗效力、研究方法、国家特异性轮状病毒伤残调整生命年(DALY)和人均国内生产总值(GDP),所有结果以2017年美元报告。

主要发现

  • 全球中位ICER为2289美元/DALY(95%不确定性区间(UI):147-38993美元)。
  • 中非共和国ICER为每DALY 85美元(95%UI:13-302美元),美国为每DALY 70599美元(95%UI:11030-263858美元)。
  • 在有资格获得Gavi支持的国家中,平均ICER为每DALY 255美元(95%UI:39-918美元)。
  • 在有资格获得PAHO revolving fund支持的国家中,平均ICER为每DALY 2464美元(95%UI:382-3118美元)。
  • 疫苗效力、疫苗成本、人均GDP和轮状病毒DALY是ICER变异的重要驱动因素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rotavirus caused an estimated 151,714 deaths from diarrhea among children under 5 in 2019. To reduce mortality, countries are considering adding rotavirus vaccination to their routine immunization program. Cost-effectiveness analyses (CEAs) to inform these decisions are not available in every setting, and where they are, results are sensitive to modeling assumptions, especially about vaccine efficacy. We used advances in meta-regression methods and estimates of vaccine efficacy by location to estimate incremental cost-effectiveness ratios (ICERs) for rotavirus vaccination in 195 countries. METHODS: Beginning with Tufts University CEA and Global Health CEA registries we used 515 ICERs from 68 articles published through 2017, extracted 938 additional one-way sensitivity analyses, and excluded 33 ICERs for a sample of 1,418. We used a five-stage, mixed-effects, Bayesian metaregression framework to predict ICERs, and logistic regression model to predict the probability that the vaccine was cost-saving. For both models, covariates were vaccine characteristics including efficacy, study methods, and country-specific rotavirus disability-adjusted life-years (DALYs) and gross domestic product (GDP) per capita. All results are reported in 2017 United States dollars. RESULTS: Vaccine efficacy, vaccine cost, GDP per capita and rotavirus DALYs were important drivers of variability in ICERs. Globally, the median ICER was $2,289 (95% uncertainty interval (UI): $147-$38,993) and ranged from $85 per DALY averted (95% UI: $13-$302) in Central African Republic to $70,599 per DALY averted (95% UI: $11,030-$263,858) in the United States. Among countries eligible for support from Gavi, The Vaccine Alliance, the mean ICER was $255 per DALY averted (95% UI: $39-$918), and among countries eligible for the PAHO revolving fund, the mean ICER was $2,464 per DALY averted (95% UI: $382-$3,118). CONCLUSION: Our findings incorporate recent evidence that vaccine efficacy differs across locations, and support expansion of rotavirus vaccination programs, particularly in countries eligible for support from Gavi, The Vaccine Alliance.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Janko MM, Joffe J, Michael D, et al. Cost-effectiveness of rotavirus vaccination in children under five years of age in 195 countries: A meta-regression analysis. Vaccine. 2022. PMID: 35643565. doi:10.1016/j.vaccine.2022.05.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。